248 related articles for article (PubMed ID: 29649684)
1. The ROME (Retrospective Observational Multicenter study on Eslicarbazepine) study: Efficacy and behavioural effects of Eslicarbazepine acetate as adjunctive therapy for adults with partial onset seizures in real life.
Assenza G; Mecarelli O; Lanzone J; Assenza F; Tombini M; Di Lazzaro V; Pulitano P
Seizure; 2018 May; 58():35-40. PubMed ID: 29649684
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
3. Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results.
Cramer JA; Colman S; Anastassopoulos KP; Grinnell T; Mehta D; Williams GR
Epilepsy Behav; 2020 Nov; 112():107312. PubMed ID: 32801102
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
[TBL] [Abstract][Full Text] [Related]
5. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
6. MONOZEB: Long-term observational study of eslicarbazepine acetate monotherapy.
Villanueva V; Bermejo P; Montoya J; Massot-Tarrús A; Galiano ML; Toledo M; Rodriguez-Uranga JJ; Bertol V; Mauri JÁ; Poza JJ; Bonet M; Castro-Vilanova MD; Ruiz-Giménez J; López-González FJ; Rodríguez-Osorio X; Tortosa-Conesa D; Ojeda J; Giner P; Garcés M; Alvarez BM; Quiroga-Subirana P; Esteve P; Baiges JJ; Hampel K
Epilepsy Behav; 2019 Aug; 97():51-59. PubMed ID: 31181429
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
[TBL] [Abstract][Full Text] [Related]
8. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
[TBL] [Abstract][Full Text] [Related]
9. Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli.
Holtkamp M; Delanty N; Sales F; Serratosa J; McMurray R; Villanueva V
Acta Neurol Scand; 2019 Jan; 139(1):49-63. PubMed ID: 30176048
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
11. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.
Jóźwiak S; Veggiotti P; Moreira J; Gama H; Rocha F; Soares-da-Silva P
Epilepsy Behav; 2018 Apr; 81():1-11. PubMed ID: 29454255
[TBL] [Abstract][Full Text] [Related]
12. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
[TBL] [Abstract][Full Text] [Related]
15. Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.
Villanueva V; Holtkamp M; Delanty N; Rodriguez-Uranga J; McMurray R; Santagueda P
J Neurol; 2017 Nov; 264(11):2232-2248. PubMed ID: 28921040
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: A multicenter audit.
Giráldez BG; Garamendi-Ruiz I; Zurita J; García A; Querol R; Campos D; Cabeza-Alvarez C; Serrano P; López-González FJ; Molins A; Serratosa JM
Acta Neurol Scand; 2019 Dec; 140(6):422-428. PubMed ID: 31498422
[TBL] [Abstract][Full Text] [Related]
17. Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate.
Velez FF; Bond TC; Anastassopoulos KP; Wang X; Sousa R; Blum D; Cramer JA
Epilepsy Behav; 2017 Mar; 68():203-207. PubMed ID: 28236698
[TBL] [Abstract][Full Text] [Related]
18. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
[TBL] [Abstract][Full Text] [Related]
19. Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy.
Holtkamp M; McMurray R; Bagul M; Sousa R; Kockelmann E
Acta Neurol Scand; 2016 Jul; 134(1):76-82. PubMed ID: 26915469
[TBL] [Abstract][Full Text] [Related]
20. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
